EUVIMEDEUVIMED entdecken
Crossref

5-Carboxamide-Substituted Barbituric Acids: Promising Scaffolds for Drug Development against Mycobacterium tuberculosis

Henok A Sahile iD, Bhuwan Awasthi iD, Jonas E Olsen iD, Houria Afshar, Sung-Won Kim, Itay Amrom, Zohra Nikjo iD, Leah Rankine-Wilson iD, Wayne W H Law, Selvarani Vimalanathan, Clement K M Tsui, John L Rubinstein iD und 2 weitere

ACS Infectious Diseases · 11.09.2026 · 12 (9) · 3191-3203

DOI: 10.1021/acsinfecdis.6c00420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 17.08.2026. Verfasst von Henok A Sahile und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, VancouverV6T 1Z3, Canada. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Barbiturates, Antitubercular Agents. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Natural Sciences and Engineering Research Council of Canada, Canada Foundation for Innovation, CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The continued spread of drug-resistant Mycobacterium tuberculosis (Mtb) necessitates the development of new chemotypes with novel modes of action. Here, we report 5-carboxamide-substituted barbituric acid as a promising scaffold for developing new drugs against Mtb. Fenoxacrim, the initial hit compound identified through phenotypic screening, demonstrated potent activity against Mtb. It is active against drug-susceptible and multidrug-resistant clinical Mtb isolates as well as against intracellular Mtb in infected THP-1 derived macrophages. Fenoxacrim demonstrates high selectivity (>73-fold) for the pathogen over several tested mammalian cell lines. Other than Mtb, fenoxacrim exhibits strong bactericidal activity against several Gram-positive pathogens, including methicillin-resistantStaphylococcus aureus (MRSA), with in vitro potency comparable to, or exceeding several clinically used antibiotics. Medicinal chemistry optimization efforts yielded new fenoxacrim analogues with improved Mtb specificity, enhanced potency, and reduced cytotoxicity. Mode-of-action studies suggest that fenoxacrim inhibits undecaprenyl pyrophosphate synthase (UPPS) and dissipates the bacterial membrane potential. Together, these findings highlight the potential of 5-carboxamidebarbituric acid derivatives as a foundation for developing new antibacterial agents with novel modes of action for the treatment of tuberculosis and other drug-resistant bacterial infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisBarbituratesAntitubercular AgentsHumansMicrobial Sensitivity TestsMacrophagesStructure-Activity RelationshipDrug Development

Stichwörter der Autor:innen

5-carboxamidebarbituric acidsfenoxacrimmultidrug resistant tuberculosistuberculosis

Substanzen

BarbituratesAntitubercular Agentsbarbituric acid

Autor:innen und Institutionen

  • Department of Medicine, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, VancouverV6T 1Z3, Canada.
  • Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, VancouverV6T 1Z3, Canada.
  • Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, 2350 Health Sciences Mall, VancouverV6T 1Z3, Canada.
  • Molecular Medicine Program, the Hospital for Sick Children, University of Toronto, 686 Bay Street, Rm. 20-9705, TorontoM5G 0A4, Canada.
  • Infectious Disease Research Laboratory, National Centre for Infectious Diseases, Singapore308442, Singapore.
  • Department of Medicine, University of British Columbia, VancouverV6T 1Z3, Canada.

ORCID-Profile: Henok A Sahile, Bhuwan Awasthi, Jonas E Olsen, Zohra Nikjo, Leah Rankine-Wilson, John L Rubinstein, Brent D G Page, Yossef Av-Gay

Förderung

  • Natural Sciences and Engineering Research Council of Canada
  • Canada Foundation for Innovation
  • CIHR
  • Canada Research Chairs program
  • TB Vets Charitable Foundation
  • Canadian Institute of Health Research (CIHR)
  • CIHR Project Grant

Zitieren

APA

Sahile, H. A., Awasthi, B., Olsen, J. E., Afshar, H., Kim, S. W., Amrom, I., Nikjo, Z., Rankine-Wilson, L., Law, W. W. H., Vimalanathan, S., Tsui, C. K. M., Rubinstein, J. L., Page, B. D. G., & Av-Gay, Y. (2026). 5-Carboxamide-Substituted Barbituric Acids: Promising Scaffolds for Drug Development against Mycobacterium tuberculosis. ACS Infectious Diseases, 12(9), 3191-3203. https://doi.org/10.1021/acsinfecdis.6c00420

Vancouver

Sahile HA, Awasthi B, Olsen JE, Afshar H, Kim SW, Amrom I, et al. 5-Carboxamide-Substituted Barbituric Acids: Promising Scaffolds for Drug Development against Mycobacterium tuberculosis. ACS Infectious Diseases. 2026;12(9):3191-3203. doi:10.1021/acsinfecdis.6c00420

BibTeX
@article{Sahile2026,
  author = {Sahile, Henok A and Awasthi, Bhuwan and Olsen, Jonas E and Afshar, Houria and Kim, Sung-Won and Amrom, Itay and Nikjo, Zohra and Rankine-Wilson, Leah and Law, Wayne W H and Vimalanathan, Selvarani and Tsui, Clement K M and Rubinstein, John L and Page, Brent D G and Av-Gay, Yossef},
  title = {5-Carboxamide-Substituted Barbituric Acids: Promising Scaffolds for Drug Development against Mycobacterium tuberculosis},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {9},
  pages = {3191--3203},
  doi = {10.1021/acsinfecdis.6c00420}
}
Kostenlos starten →